Syros Pharmaceuticals Q3 2024 Earnings Report $0.03 0.00 (-10.86%) As of 03/28/2025 03:59 PM Eastern Earnings HistoryForecast Syros Pharmaceuticals EPS ResultsActual EPS-$0.68Consensus EPS -$0.76Beat/MissBeat by +$0.08One Year Ago EPS-$1.35Syros Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASyros Pharmaceuticals Announcement DetailsQuarterQ3 2024Date10/31/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSYRS Earnings History Remove Ads Syros Pharmaceuticals Earnings HeadlinesSyros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.comMarch 29 at 2:23 AM | americanbankingnews.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 345.9% in MarchMarch 27 at 3:05 AM | americanbankingnews.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…March 30, 2025 | Paradigm Press (Ad)Syros Pharmaceuticals (SYRS) to Release Quarterly Earnings on WednesdayMarch 24, 2025 | americanbankingnews.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Rating of "Hold" by AnalystsMarch 23, 2025 | americanbankingnews.comStockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)March 23, 2025 | americanbankingnews.comSee More Syros Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Syros Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Syros Pharmaceuticals and other key companies, straight to your email. Email Address About Syros PharmaceuticalsSyros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.View Syros Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
